Cognition Therapeutics, Inc.
CGTX
$1.01
-$0.03-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.95% | -12.02% | -13.65% | -19.93% | -16.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.86% | -20.13% | -11.43% | -23.24% | -9.84% |
| Operating Income | 30.86% | 20.13% | 11.43% | 23.24% | 9.84% |
| Income Before Tax | 49.16% | 41.21% | 30.86% | 18.34% | -6.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.16% | 41.21% | 30.86% | 18.34% | -6.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.16% | 41.21% | 30.86% | 18.34% | -6.15% |
| EBIT | 30.86% | 20.13% | 11.43% | 23.24% | 9.84% |
| EBITDA | 30.83% | 20.08% | 11.38% | 23.25% | 9.84% |
| EPS Basic | 70.57% | 64.89% | 60.41% | 49.59% | 28.70% |
| Normalized Basic EPS | 70.76% | 65.08% | 60.60% | 49.13% | 28.22% |
| EPS Diluted | 71.11% | 64.89% | 60.03% | 49.45% | 28.11% |
| Normalized Diluted EPS | 70.76% | 65.08% | 60.60% | 49.13% | 28.22% |
| Average Basic Shares Outstanding | 64.46% | 70.83% | 83.82% | 70.85% | 55.79% |
| Average Diluted Shares Outstanding | 64.46% | 70.83% | 83.82% | 70.85% | 55.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |